The definition of what constitutes a heart attack, also known as myocardial infarction (MI), and the data points used to create a best practices report for cardiac patient care has created a storm of controversy in the European cardiac field. The Clinical StudyThe...
AbbVie
Category
Rheumatoid Arthritis Upadacitinib Gets Positive Opinion from EMA CHMP & Now Awaits Final Authority Marketing Authorization
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for AbbVie’s RINVOQ™( Upadacitinib), a once-daily selective and reversible JAK inhibitor, for the treatment of adult patients with moderate to severe...
Kaiser Permanente Participating in AbbVie-Sponsored International Clinical Trial Targeting Ovarian Cancer with PARP Inhibitor Called Veliparib
Kaiser Permanente Research radio recently interviewed Dr. Michael A Bookman, an oncologist and investigator with Kaiser, discussing his participation in an international clinical trial sponsored by AbbVie, focusing on a PARP inhibitor called Veliparib to treat ovarian...
AbbVie Acquires Seattle Area Start-Up to Further Bolster Its Early Stage Oncology Pipeline
Biopharma developing cancer therapies are in demand as the growing industry vies for bigger and more valuable pipelines. Seattle-based, privately held Mavupharma was the latest to feel the demand with its acquisition by AbbVie, which seeks to bolster its early-stage...
AbbVie Will Acquire Allergan in $63 Billion Merger
AbbVie and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of...
AbbVie Resumes CANOVA Multiple Myeloma Trial After FDA Lifts Partial Hold
AbbVie announced the U.S. FDA has lifted the partial clinical hold placed on CANOVA, a Phase 3 trial evaluating venetoclax (Venclexta or Venclyxto) for the treatment of relapsed/refractory multiple myeloma. The CANOVA trial is evaluating venetoclax in combination with...
VCU Massey Cancer Center Identifies Novel Combo Drug Effective Against AML During Preclinicals
Scientists at VCU Massey Cancer Center found that a novel combination of drugs is effective against acute myeloid leukemia (AML) in preclinical models. The findings, recently published in the Journal of Cancer Research, could lead to new and improved treatments for...
AbbVie Active at ASCO with Over 40 Abstracts Highlighting its Oncology Pipeline
AbbVie announced in a press release it plans on over 40 abstracts to form its oncology pipeline at this year’s ASCO and EHA medical meetings in June. Some key highlights include: Results from the Phase 3 CLL 14 trial of venetoclax plus obinutuzumab in previously...
AbbVie’s Treatment for Plaque Psoriasis, Skyrizi, Approved by FDA
AbbVie announced the FDA approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The FDA approval of Skyrizi was based on...
AbbVie Treatment Approved For Moderate to Severe Psoriasis
Psoriasis afflicts approximately 7.5 million Americans and represents the most prevalent autoimmune disease in the United States reports drug producer AbbVie. In response, the Chicago-based industry sponsor has developed risankizumab-rzaa (SKYRIZI™), also known as...
AbbVie Walks Away from Inflammatory & Autoimmune Drug Dev Partnership
EndPoints’ Natalie Grover reports that AbbVie and San Francisco-based Principia have parted ways. The two had signed a collaborative drug development deal which provided $15 million in upfront payments to the new publicly traded biotech. See EndPoints for the story.
Hidradenitis Suppurativa Patient Website: Does It Live Up to Its Name?
Recently, a TrialSite News reader—a Hidradenitis Suppurativa (HS) patient—brought a website to our attention. Apparently, this individual, who has been struggling with HS, was searching for an HS doctor. She Google-searched the search term “best Hidradenitis...
PharmaWatch: German Boehringer Ingelheim Taking on an American Thorny Thicket
Delaware federal court Judge Richard Lloret recently ordered AbbVie to immediately produce important Humira® documentation to defendant Boehringer Ingelheim (BI) in what is turning out to be a dramatic legal thriller. The stakes are big. Humira® is a $20 billion drug...
Hidradenitis Suppurativa and Cancer: Is There a Connection?
Hidradenitis Suppurativa: A Horrible Disease Afflicting Millions Worldwide TrialSite News has been actively covering the serious skin disease and potential autoimmune-related disorder Hidradenitis Suppurativa (HS). Anywhere from 1 to 4 % of the developed world’s...
AbbVie and Abbott Labs Settle with Government to Resolve Claims & Kickback Allegations
Both Abbott Laboratories and AbbVie Inc. will settle with the federal government for allegations that they employed kickbacks and unlawful methods of marketing and promotion to sell more TriCor® subscriptions. The allegations are based on activities between 2006 to...
California Sues AbbVie for Alleged Humira Kickback Scheme
TrialSite News include link to the actual lawsuit. The California Department of Insurance sued AbbVie last month for allegedly orchestrating a wide ranging kickback scheme to illegally boost prescriptions of its best-selling Humira drug. Filed in Alameda County...
Abbvie Paid Docs to Overprescribe Humira, CAL Alleges in Suit
Chicago Tribune writer Sudhin Thanawala reports that pharmaceutical giant AbbVie illegally plied doctors with cash, gifts and services to prescribe one of the world's best-selling drugs, Humira, despite its potentially deadly complications, a California official said...